Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays by Pas, S.D. (Suzan) et al.
JOURNAL OF CLINICAL MICROBIOLOGY,
0095-1137/00/$04.0010
Aug. 2000, p. 2897–2901 Vol. 38, No. 8
Copyright © 2000, American Society for Microbiology. All Rights Reserved.
Development of a Quantitative Real-Time Detection Assay for
Hepatitis B Virus DNA and Comparison with Two
Commercial Assays
SUZAN D. PAS,1 EDWIN FRIES,1 ROBERT A. DE MAN,2 ALBERT D. M. E. OSTERHAUS,1 AND
HUBERT G. M. NIESTERS1*
Departments of Virology,1 and Gastroenterology,2 University Hospital Rotterdam, Rotterdam, The Netherlands
Received 2 March 2000/Accepted 1 June 2000
A highly reproducible and sensitive real-time detection assay based on TaqMan technology was developed for
the detection of hepatitis B virus (HBV) DNA and compared with two commercially available assays. The assay
was validated with the Viral Quality Control panel, which also includes EUROHEP HBV DNA standards. This
real-time PCR detection system had a dynamic range of 373 to 1010 genome copies per ml and showed an
excellent correlation with both the commercial HBV Digene Hybrid Capture II microplate assay (Digene
Diagnostics) and the HBV MONITOR assay (Roche Diagnostics). To demonstrate its clinical utility, four
chronically HBV-infected patients treated with lamuvidine were monitored using the three different assays.
From the results we concluded that this assay is an excellent alternative for monitoring of HBV-infected
patients in routine diagnostics and clinical practice, enabling the analysis of a large dynamic range of HBV
DNA in a single, undiluted sample.
It has been estimated that worldwide approximately 300
million individuals are chronically infected with hepatitis B
virus (HBV). The measurement of HBV DNA in serum has
become an important tool to identify individuals with high viral
replication, to monitor patients on therapy, and to predict
whether antiviral therapy will be successful. With the introduc-
tion of new antivirals like lamivudine [(2)29,39-dideoxy-39-
thiacytidine], close monitoring of patients has become increas-
ingly important due to the occurrence of antiviral drug-
resistant virus strains or the presence of flares after withdrawal
from antiviral therapy (6, 11).
Several homemade and commercial molecular assays have
been used to quantify the level of HBV DNA in serum samples
(3, 7–10, 13, 18). However, due to the lack of standardization
and the inability of these assays to quantify the whole dynamic
range over which HBV DNA should be measured, different
assays and serum dilutions have to be used for adequate mon-
itoring of antiviral therapy. In this paper, we describe the
results of the validation of a real-time PCR detection assay,
based on TaqMan technology, for the detection of HBV DNA
in serum samples. This assay is able to measure the large
dynamic range in which HBV DNA can be present in chroni-
cally infected patients.
The assay is based on linearity, takes into account intra- and
interassay variability, and can be performed in a routine set-
ting. The real-time PCR detection assay is validated using the
viral quality control (VQC) HBV DNA panel (CLB, Amster-
dam, The Netherlands) and compared with other commercially
available quantitative assays (HBV Digene Hybrid Capture II
microplate assay [Digene, Gaithersburg, Md.] and HBV
MONITOR assay [Roche Diagnostics, Almere, The Nether-
lands]). Furthermore, to demonstrate its use in clinical prac-
tice, four chronically HBV-infected patients were monitored
over a period of time in which they received antiviral treatment.
MATERIALS AND METHODS
Patients and clinical samples. The clinical samples used for this study were
well-characterized samples obtained from previous study protocols. Additional
samples for the correlation and precision study were routine samples from our
Virology Department. Samples requiring dilution, including the VQC standards,
were diluted in serum known to be HBV DNA negative. All aliquots were stored
frozen at 220°C or a lower temperature until use. For the specificity analysis,
samples (kindly provided by the Blood Bank Rotterdam) obtained from 200
healthy blood donors were used.
For a standardized evaluation, we obtained an international reference VQC
plasma preparation panel (CLB) containing well-characterized HBV DNA levels
including EUROHEP HBV DNA standard A. These samples were tested ex-
tensively and contain HBV DNA levels ranging from no HBV DNA to 4.37 3
107 HBV molecules per ml.
DNA extraction method for real-time PCR detection assay. For the isolation of
HBV DNA from serum, the High Pure Viral Nucleic Acid kit (Roche Diagnos-
tics) was used. Briefly, 200 ml of serum was added to 200 ml of a freshly prepared
working solution containing 6 M guanidine-HCl, 10 mM urea, 10 mM Tris-HCl,
and 20% (vol/vol) Triton X-100 supplemented with 1 mg of poly(A)1 carrier
RNA and 800 mg of proteinase K. After incubation for 10 min at 72°C, 100 ml of
isopropanol was added and the mixture was transferred onto a High Pure filter
tube combined with a collection tube. The filter tube was centrifuged for 1 min
at 5,000 3 g in a standard tabletop centrifuge at room temperature. After being
washed twice with 450 ml of buffer (20 mM NaCl, 2 mM Tris-HCl [pH 7.5] in
ethanol), the filter was placed in a new collection tube and 50 ml of RNase- and
DNase-free water was added to elute the DNA. This resulted in fourfold con-
centration of the original input material.
HBV Digene Hybrid Capture II microplate assay. The HBV Digene Hybrid
Capture II microplate assay was performed in accordance with the manufactur-
er’s protocol. Briefly, 30 ml of serum samples, controls, and standards or cali-
brators ranging from 0.5 to 6,000 pg/ml (equivalent to 1.42 3 105 to 1.7 3 109
HBV DNA copies per ml) were incubated with 30 ml of sodium hydroxide
solution (denaturation reagent) for 30 min at 65°C in a 96-well microplate. No
additional sample preparation step was needed. After preparation of the probe
mixture, 30 ml of RNA HBV probe was added to each well and the plate was
incubated for 1 h at 65°C. To capture the DNA-RNA hybrids, 75 ml of each
solution in the microplates was transferred to the corresponding well of the
anti-RNA-DNA hybrid antibody-coated capture microplate and subsequently
shaken at room temperature for 1 h. The hybrid was detected using an anti-
hybrid antibody conjugated to alkaline phosphatase and detected with the chemi-
luminiscent substrate CDP-star with Emerald II.
To enable detection of HBV DNA levels of less than 1.42 3 105 copies per ml,
the ultrasensitive format of the assay was used. Briefly, 1-ml serum samples and
controls along with 50 ml of precipitation buffer were centrifuged at 33,000 3 g
for 110 min at 4°C in a Hereaus Stratos Biofuge. The supernatant was discarded,
and the precipitated virus was dissolved in 25 ml of diluent. This procedure yields
a 30-fold increase in sensitivity and enhances the lower detection limit of the
assay to approximately 8,000 HBV copies/ml.
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HBV MONITOR assay. HBV DNA levels were monitored using the Roche
Molecular Systems Amplicor HBV MONITOR Assay in accordance with the
instructions of the manufacturer. Briefly, we subjected 50 ml of serum to precip-
itation by polyethylene glycol 8000, followed by sodium hydroxide lysis and
neutralization. For PCR, a primer set which amplifies a 104-bp fragment of the
precore and core gene was used. During the amplification, internal standard (IS)
DNA was coamplified with the target DNA. One of the primers was labeled with
biotin. After amplification, two aliquots were pipetted into separate wells of a
streptavidin-coated plate. The PCR products of the HBV core gene and the IS
were separately hybridized with a dinitrophenyl-labeled HBV- or IS-specific
probe. The hybridization products were detected colorimetrically with an anti-
dinitrophenyl-alkaline phosphatase conjugate and para-nitrophenylphosphate
substrate.
The amount of HBV DNA was calculated from the ratio of the HBV-specific
well to the IS-specific well. The number of copies per ml was calculated from a
standard curve prepared from each amplification run, ranging from 0 to 106 HBV
copies per ml. The detection limit of the assay, according to the manufacturer, is
400 genome equivalents per ml. The dynamic range of the assay in the format we
used was 400 to 4 3 107 genome equivalents per ml.
Real-time PCR detection assay. The PCR primers and probe used were de-
signed using Primer Express software (PE Biosystems, Nieuwerkerk a/d IJssel,
The Netherlands). Amplification was performed in a 50-ml reaction mixture
containing 23 TaqMan Universal MasterMix (PE Biosystems), 45 pmol of for-
ward primer (59-GGA.CCC.CTG.CTC.GTG.TTA.CA-39, nucleotides 184 to
203), 45 pmol of reverse primer (59-GAG.AGA.AGT.CCA.CCM.CGA.GTC.T
AG.A-39, nucleotides 273 to 249), 15 pmol of TaqMan probe (59-FAM-TGT.
TGA.CAA.RAA.TCC.TCA.CCA.TAC.CRC.AGA-TAMRA-39, nucleotides 218
to 247), and 10 ml of isolated DNA. The primers and probe were selected in the
pre-S gene of the HBV genome and generated a product of 89 bp.
All isolations and amplification reactions were performed in duplicate. After
preparation of the reaction mixtures in 96-well plates, the plates were centrifuged
at 1,200 rpm for 1 min in a Rotina 48R swing rotor (Hettig, Tuttlingen, Ger-
many) to remove small air bubbles in the vessels. Amplification and detection
were performed with an ABI Prism 7700 Sequence Detection System (PE Bio-
systems). After incubation for 2 min at 50°C, which enables uracil N9-glycosylase
(present in the 23 Universal MasterMix) to inactivate possible contaminating
amplicons, incubation for 10 min at 95°C allowed AmpliTaq Gold polymerase to
activate and inactivate the uracil N9-glycosylase. The PCR cycling program con-
sisted of 45 two-step cycles of 15 s at 95°C and 60 s at 60°C.
For preparation of an external standard containing noninfectious material,
HBV DNA (3.2 kb) was cloned into vector pBR322 (kindly provided by R.
Heijtink, Erasmus University, Rotterdam, The Netherlands) and transformed
into INVaF9 One Shot Escherichia coli bacteria (InVitrogen, Leek, The Neth-
erlands). Plasmid DNA was isolated on the Vistra Labstation (Amersham Phar-
macia Biotech, Roosendaal, The Netherlands). For standardization of the real-
time PCR detection assay, a standard curve of the plasmid ranging from 10
million to 670 copies/ml and a run control of 30,000 copies/ml (CLB) were
included in each run. Validation of the plasmid controls was done with the VQC
panel (CLB).
Data analysis and statistics. Analysis of raw data was done with the Sequence
Detector V1.6.3 software (PE Biosystems). Data were collected at the annealing
step (60°C) of every cycle, and the threshold cycle (Ct) for each sample was
calculated by determining the point at which the fluorescence exceeded the
threshold limit, which was set at 0.04 U. The standard curve was calculated
automatically by plotting the Ct values against each standard of known concen-
tration and calculation of the linear regression line of this curve. Calculation of
the correlation coefficient (r2) was done for each run, and the minimal value was
0.98. Sample copy numbers were calculated by interpolation of the experimen-
tally determined standard curve. In order to determine the extent to which the
data obtained were in agreement, the data were also analyzed as described by
Bland and Altman (1), whose method is based on comparison of the differences
between measurements for the same sample by plotting of the differences against
the average. All other statistical analysis was performed using the functions of
the SPSS (version 8.0) software.
RESULTS
Precision study. Inter- and intra-assay variability was deter-
mined by isolating one-third-log serial dilutions of a serum
sample ranging from 5.49 3 109 to 3.82 3 102 HBV DNA
copies per ml. Interassay variability was determined by isolat-
ing quadruplicates of the dilution series on three consecutive
days (n 5 12), while intra-assay variability was evaluated by
running quadruplicates of one isolation on one plate (n 5 4).
Table 1 shows the mean Ct values, the percent coefficient of
variation (%CV), and the amount of input HBV DNA within
a run and between separate runs. There is no statistically sig-
nificant difference between the %CV of interassay variability
(mean, 1.85) and the %CV of intra-assay variability (mean,
1.65) (P 5 0.761).
Specificity. In order to determine the specificity of the real-
time PCR detection assay, 200 anti-hepatitis B surface antigen-
negative EDTA-plasma samples were analyzed. None of the
samples showed false-positive reactions in duplicate. Four
samples had to be reisolated and retested because of inconsis-
tency between the duplicates but showed no reactivity in the
second analysis.
Validation of the real-time PCR detection assay. We first
validated the HBV plasmid standard curve of the real-time
PCR detection assay using the VQC panel, containing both
HBV DNA-negative samples and well-characterized samples
ranging from 4.27 3 107 to 113 copies per ml.
The log10 theoretical HBV DNA concentrations were com-
pared to the log10 HBV DNA concentrations determined by
the real-time PCR detection assay, which were calculated
through interpolation of the Ct values from the standard curve.
Regression analysis showed that the slope approached 1.0
(95% confidence interval, 0.83 to 1.04) and the y intercept
approached 0 (95% confidence interval, 20.30 to 0.64; Fig.
1A). The correlation coefficient (r2 5 0.089) and high P value
(P 5 0.610) of the Bland-and-Altman comparison indicated no
significant difference between the values obtained (Fig. 1B).
The VQC sample with a viral HBV copy number of 373/ml
still generated a detectable signal in the real-time PCR detec-
tion assay, while the sample with 113 copies/ml could not be
detected in the format used.
Correlation between the HBV real-time PCR detection assay
and commercially available HBV DNA assays. The HBV DNA
real-time PCR detection assay was compared with two com-
mercially available assays to determine its usefulness for a
clinical virology laboratory. For routine diagnostics, we se-
lected sera for which the HBV DNA value was determined
using the Digene Hybrid Capture II microplate assay or the
Roche HBV MONITOR assay.
One hundred eighteen HBV DNA-positive samples were
tested in both the Digene assay and the real-time PCR detec-
tion assay. These samples were within the range of the Digene
assay in the standard or sensitive format (range, 8 3 103 to
1.7 3 109 copies of HBV DNA per ml). The log values of all
TABLE 1. Study of intra- and interassay variability of the HBV
DNA real-time PCR detection assay to determine its precision
Sample Amt of input HBV DNA(no. of copies/ml)
Mean Ct (%CV)
Intra-assaya Interassayb
V15 3.82 3 102 43.97 (4.67) 44.06 (3.40)
V14 1.03 3 103 40.49 (7.62) 40.79 (5.71)
V13 1.15 3 103 39.04 (5.12) 37.90 (1.65)
V12 3.44 3 103 37.33 (1.34) 36.87 (1.50)
V11 3.10 3 104 34.64 (0.70) 34.83 (1.01)
V10 9.30 3 104 33.22 (0.43) 33.61 (1.11)
V9 2.79 3 105 31.82 (1.11) 31.46 (1.55)
V8 8.37 3 105 29.76 (0.84) 30.02 (0.84)
V7 2.51 3 106 28.35 (0.78) 28.35 (0.94)
V6 7.53 3 106 26.86 (0.60) 26.76 (1.14)
V5 2.26 3 107 24.48 (0.35) 24.93 (1.27)
V4 6.78 3 107 23.25 (0.12) 23.35 (1.76)
V3 2.03 3 108 21.73 (0.54) 21.79 (1.27)
V2 6.10 3 108 20.23 (0.53) 20.40 (1.61)
V1 1.83 3 109 19.21 (0.52) 18.92 (1.73)
V0 5.49 3 109 17.62 (1.20) 17.38 (3.05)
a Mean %CV, 1.65; n 5 4.
b Mean %CV, 1.85; n 5 12.
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samples were plotted, and regression analysis showed a slope
of 1.004 (95% confidence interval, 0.944 to 1.064), while the y
intercept approached 0 (0.038, 95% confidence interval,
20.576 to 0.314). Bland-and-Altman analysis furthermore in-
dicated that the slope did not significantly differ from 0
(20.053, 95% confidence interval, 20.112 to 0.005) and the y
intercept approached 0 (0.304, 95% confidence interval,
20.119 to 0.730), indicating no difference in detection between
the Digene Hybrid Capture II microplate assay and the real-
time PCR detection assay for HBV.
To compare the HBV MONITOR assay with the HBV
DNA real-time PCR detection assay, 93 serum samples were
tested in both assays. These samples were within the range of
the HBV MONITOR assay. Regression analysis showed a
slope of 0.995 (95% confidence interval, 0.921 to 1.069) and
that the y intercept approached 0 (0.247; 95% confidence in-
terval, 20.195 to 0.690). Bland-and-Altman analysis indicated
that both the slope (20.056, 95% confidence interval, 20.128
to 0.016) and the y intercept (0.114, 95% confidence interval,
20.325 to 0.553) did not significantly differ from 0, indicating
no difference between the assays. A summary of the results is
given in Fig. 2A (direct comparison) and B (Bland-and-Altman
analysis).
Clinical monitoring. To further demonstrate the clinical
utility of the HBV DNA real-time PCR detection assay, four
lamuvidine-treated chronically HBV-infected patients were
monitored with all three assays, the Digene Hybrid Capture II
microplate assay, the Roche MONITOR assay, and the HBV
DNA real-time PCR detection assay. For both the Digene
Hybrid Capture II microplate assay and the Roche HBV
MONITOR assay, the appropriate dilutions were made in or-
der to enable accurate determination of HBV DNA in the
range of the assays. In Fig. 3, the calculated log10 HBV DNA
levels (copies per ml) measured with the three different assays
are plotted. All four patients showed a rapid decline in HBV
DNA during treatment with lamuvidine, and there was a good
correlation of the three different assays.
DISCUSSION
In this paper, we have presented a quantitative assay based
on the TaqMan real-time PCR detection methodology for the
detection of HBV DNA. Furthermore, we have demonstrated
this detection system to be highly reproducible, with no statis-
tically significant difference in variability, as well as to have the
ability to detect HBV DNA between approximately 373 and 10
billion copies per ml without any further sample dilution or
concentration. The low variability of this assay makes a twofold
decrease or increase in the serum HBV DNA level already
significant. The high reproducibility and linearity of the assay
FIG. 1. Linear (A) and Bland-and-Altman (B) comparisons of the real-time
HBV DNA PCR detection assay and the DNA concentration expected from the
VQC panel. Plotted are the calculated regression line (solid line) of these values
and the 95% confidence intervals of the mean (broken lines). In panel B, an
additional reference line (y 5 0; broken-and-dotted line) is plotted to indicated
that the data are well within the 95% confidence interval of the expected results.
FIG. 2. Correlation of the Digene Hybrid Capture (HC) II microplate assay
and the Roche HBV MONITOR assay with the HBV DNA real-time PCR
detection assay. The log10 DNA concentrations were calculated for a set of 211
randomly selected clinical samples, 118 of which were detected by the Digene
Hybrid Capture II microplate assay (A). Panel B shows the results of Bland-
and-Altman analysis performed on both comparisons.
VOL. 38, 2000 HBV DNA ASSAYS 2899
described proved to be comparable to those of two commer-
cially available assays.
More than a decade has passed since the introduction and
use of PCR technology for the detection of HBV DNA in
serum. Although different commercial assays have become
available enabling an easy-to-use platform, there is still
progress to be made, since the detection range of these assays
was shown to be limited. Only the Digene Hybrid Capture II
microplate assay was able to detect HBV DNA over a wide
range (8 3 103 to 1.7 3 109 copies per ml), although in the
lower range a sample concentration step needs to be per-
formed. The Roche HBV MONITOR assay is used for quan-
titative HBV detection in the lower range of HBV DNA de-
tection in patients (400 to 4 3 107 copies/ml). The high
variation of the HBV MONITOR assay within the lower de-
tection range, which can even be more than 100%, is the main
disadvantage of this assay (13). The real-time PCR detection
assay described here had a good correlation with both the
Digene Hybrid Capture II microplate assay and the Roche
HBV MONITOR assay and could be used for the monitoring
of patients undergoing antiviral treatment. Regression analysis
indicated that the standardization based on the VQC panel
resulted in a large dynamic range and that data from all of the
assays were interchangeable. Since it is usually not known in
which range the HBV DNA level of a given sample is to be
expected, especially when patients are receiving antiviral treat-
ment, repeated testing is often necessary (13). With the real-
time detection assay described here, this problem is largely
overcome. Furthermore, since the introduction of TaqMan
technology, more cumbersome techniques for PCR quantita-
tion seem to have become obsolete, due to the ability of this
technology to quantify HBV DNA rather easily, without the
need for the further PCR amplicon processing steps usually
required to detect specific sequences (5).
It has often been suggested that in-house PCR assays suffer
from problems with standardization, false positivity, or con-
tamination, making them unsuitable for routine clinical diag-
nostic use (14, 16). Quality control programs have indeed in-
dicated that this is a problem (2, 15, 17). It should, however, be
realized that for both commercial and in-house assays, sample
preparation is still the most difficult step to perform and to
automate. Handling of samples and opening of tubes during
sample preparation should be carried out under good labora-
tory practice principles in order to limit the problem of con-
tamination. The complete abolishment of postamplification
handling is an additional factor in limiting contamination. Our
data further indicate that by using two independent isolates for
one sample in our assay, the problem of false positivity is more
easily observed and therefore controlled. Furthermore, partic-
ipation in external quality control programs, as well as the
continuous use of well-standardized validation panels, should
further guarantee laboratory performance. Available standard-
ized materials, like universal amplification mixtures, primers,
and probes, for real-time PCR detection assays leave the input
DNA as the only unknown factor. A further point of attention
remains the possible inhibition of the amplification reaction by
unknown components in the clinical sample. Inclusion of in-
ternal markers and selection of appropriate sample prepara-
tion devices and methods should limit this problem. We have,
for instance, shown that certain sample preparation methods
are better than others at removing the inhibitory effect of
heparin (12).
Collectively, our data show that HBV DNA quantitation
with the real-time PCR detection technique resulted in a sen-
sitive and highly reproducible assay, the results of which cor-
related well with those obtained with commercially available
assays while offering the advantage of a wide dynamic range.
REFERENCES
1. Bland, J. M., and D. G. Altman. 1995. Comparing methods of measurement:
why plotting difference against standard method is misleading. Lancet 346:
1085–1087.
2. Bootman, J. S., and P. A. Kitchin. 1992. An international collaborative study
FIG. 3. Clinical courses of four chronically HBV-infected patients during lamuvidine treatment (A to D). The calculated log10 DNA concentrations (y axis) are
plotted against time after start of therapy (hours). The patients were monitored with the HBV Digene Hybrid Capture II microplate assay (h), the HBV MONITOR
assay ({), and HBV real-time PCR detection assay ().
2900 PAS ET AL. J. CLIN. MICROBIOL.
to assess a set of reference reagents for HIV-1 PCR. J. Virol. Methods
37:23–41.
3. Butterworth, L. A., S. L. Prior, P. J. Buda, J. L. Faoagali, and W. G.
Cooksley. 1996. Comparison of four methods for quantitative measurement
of hepatitis B viral DNA. J. Hepatol. 24:686–691.
4. Heermann, K.-H., W. H. Gerlich, M. Chudy, S. Schaefer, and R. Thomssen,
The Eurohep Pathobiology Group. 1999. Quantitative detection of hepatitis
B virus DNA in two international reference plasma preparations. J. Clin.
Microbiol. 37:68–73.
5. Honkoop, P., R. A. de Man, and H. G. Niesters. 1998. Quantitative assess-
ment of hepatitis B virus DNA during a 24-week course of lamivudine
therapy. Ann. Intern. Med. 128:697.
6. Honkoop, P., H. G. Niesters, R. A. de Man, A. D. Osterhaus, and S. W.
Schalm. 1997. Lamivudine resistance in immunocompetent chronic hepatitis
B. Incidence and patterns. J. Hepatol. 26:1393–1395.
7. Janssen, H. L., Y. A. Schoenmaker-Weber, H. Kruining, S. W. Schalm, and
R. A. Heijtink. 1993. Quantitative assessment of hepatitis B virus DNA in
chronic hepatitis B: comparison of two solution hybridization assays. J. Med.
Virol. 40:307–312.
8. Kessler, H. H., K. Pierer, E. Dragon, H. Lackner, B. Santner, D. Stunzner,
E. Stelzl, B. Waitzl, and E. Marth. 1998. Evaluation of a new assay for HBV
DNA quantitation in patients with chronic hepatitis B. Clin. Diagn. Virol.
9:37–43.
9. Krajden, M., J. Minor, L. Cork, and L. Comanor. 1998. Multi-measurement
method comparison of three commercial hepatitis B virus DNA quantifica-
tion assays. J. Viral Hepatol. 5:415–422.
10. Lai, V. C. H., R. Guan, M. L. Wood, S. K. Lo, M. F. Yuen, and C. L. Lai. 1999.
Nucleic acid-based cross-linking assay for detection and quantification of
hepatitis B virus DNA. J. Clin. Microbiol. 37:161–164.
11. Niesters, H. G., P. Honkoop, E. B. Haagsma, R. A. de Man, S. W. Schalm,
and A. D. Osterhaus. 1998. Identification of more than one mutation in the
hepatitis B virus polymerase gene arising during prolonged lamivudine treat-
ment. J. Infect. Dis. 177:1382–1385.
12. Niesters, H. G., J. van Esser, E. Fries, K. C. Wolthers, J. Cornelissen, and
A. D. Osterhaus. 2000. Development of a real-time quantitative assay for
detection of Epstein-Barr virus. J. Clin. Microbiol. 38:712–715.
13. Noborg, U., A. Gusdal, E. K. Pisa, A. Hedrum, and M. Lindh. 1999. Auto-
mated quantitative analysis of hepatitis B virus DNA by using the Cobas
Amplicor HBV Monitor test. J. Clin. Microbiol. 37:2793–2797.
14. Persing, D. H. 1991. Polymerase chain reaction: trenches to benches. J. Clin.
Microbiol. 29:1281–1285.
15. Quint, W. G. V., R. A. Heijtink, J. Schirm, W. H. Gerlich, and H. G. M.
Niesters. 1995. Reliability of methods for hepatitis B virus DNA detection.
J. Clin. Microbiol. 33:225–228.
16. Sia, I. G., and R. Patel. 2000. New strategies for prevention and therapy of
cytomegalovirus infection and disease in solid-organ transplant recipients.
Clin. Microbiol. Rev. 13:83–121.
17. Zaaijer, H. L., H. T. Cuypers, H. W. Reesink, I. N. Winkel, G. Gerken, and
P. N. Lelie. 1993. Reliability of polymerase chain reaction for detection of
hepatitis C virus. Lancet 341:722–724.
18. Zaaijer, H. L., F. ter Borg, H. T. Cuypers, M. C. Hermus, and P. N. Lelie.
1994. Comparison of methods for detection of hepatitis B virus DNA. J. Clin.
Microbiol. 32:2088–2091.
VOL. 38, 2000 HBV DNA ASSAYS 2901
